All articles tagged with #melanoma
Moderna and Merck reported positive Phase 3 results for a personalized mRNA cancer vaccine, intismeran autogene, in melanoma patients. While the therapy remains investigational, early data suggests it reduces recurrence when combined with immunotherapy. Experts highlight the potential for personalized treatments across various cancers, though access and cost remain significant hurdles.
A personalized mRNA melanoma vaccine showed promising results in a Phase 3 trial, signaling the potential for mRNA-based vaccines to treat other cancers, with trials already underway for lung and pancreatic cancers; however, full data remain pending and political/regulatory factors could influence future development.
Merck and Moderna announced that the intismeran (mRNA-4157) adjuvant vaccine, when combined with Keytruda, improved recurrence-free survival and distant metastasis-free survival in a phase 3 melanoma trial, renewing optimism for personalized neoantigen vaccines and potentially reshaping oncology if data readouts support broader use; regulators will be engaged for potential approvals, and the news spurred biotech stock gains while highlighting a growing field of mRNA cancer therapies from Arcturus, BioNTech, Strand Therapeutics and others.
Personalized mRNA cancer vaccines from Moderna and Merck are showing promising late-stage results in cancers such as melanoma, pancreatic and brain tumors by training the immune system to recognize tumor-specific mutations. When combined with immunotherapy, these vaccines have reduced cancer recurrence and extended remission in some patients. More than 120 trials since the early 2000s illustrate ongoing progress and optimization of targets and combinations, though bringing an mRNA cancer vaccine to the public could take 10–15 years amid funding shifts.
A 33-year-old mom-to-be noticed a mole on her back evolving from a benign-looking freckle into malignant melanoma. After a biopsy confirmed cancer, she underwent a wide local excision and a sentinel lymph node biopsy under general anesthesia in late pregnancy, and delivered a healthy baby. Medical guidance notes melanoma can occur during pregnancy but pregnancy itself does not significantly raise risk, and treatment should not be delayed when cancer is diagnosed. Early detection and prompt treatment are crucial for prognosis.
Moderna’s shares jumped after Merck and Moderna announced that their Phase III melanoma trial of intismeran autogene with KEYTRUDA met its endpoints, a readout that was effectively foreshadowed by pre-announced signals: a fully enrolled study, Merck covering about half the trial cost, and prior commentary that implied a big move could come. The stock rose to around $145, within a 52-week range of roughly $22–$174, despite Moderna’s weaker 2025 results and restructuring. The piece highlights how identifying funded, binary events in a pipeline—well before a readout—can inform portfolio strategies, as demonstrated by Moderna’s surge.
Topline results from a large trial show Moderna and Merck’s cancer vaccine, intismeran autogene, reduced recurrence or spread of surgically removed melanoma, signaling a milestone after years of doubt and pandemic-related hurdles—though some scientists urge waiting for fuller data and longer follow-up before declaring a definitive breakthrough.
The Washington Post profiles Mark Orwig and other melanoma patients in a Moderna/M Merck trial testing an mRNA-based cancer vaccine. Early results suggest the vaccine could prevent cancer recurrence after surgery, a finding experts say could transform cancer care and accelerate FDA approval, despite participants experiencing side effects and a tough recovery.
Moderna and Merck reported a personalized mRNA cancer vaccine used with Keytruda that reduced melanoma recurrence and spread in a trial of more than 1,000 patients, with five-year data from earlier results showing about a 50% drop in recurrence and a 59% drop in spread versus Keytruda alone; if approved, thousands of melanoma patients could benefit in the first years, and trials in other cancers (lung, bladder, kidney, pancreatic, stomach) are ongoing with results expected in the coming years.
Moderna’s personalized cancer vaccine mRNA-4157 (intismeran autogene) paired with Merck’s Keytruda hit key Phase 3 melanoma endpoints, delivering a 49% reduction in recurrence or death versus Keytruda alone and sparking a 177% one‑day stock surge before shares retraced about 20% as investors took profits; Moderna’s pipeline spans nine Phase 2/3 studies across melanoma, NSCLC, bladder and kidney cancers, despite a $950 million settlement and a norovirus program setback, while Merck’s KEYTRUDA franchise remains a critical driver for oncology growth.
Moderna and Merck reported Phase 3 results for intismeran autogene (a personalized mRNA cancer vaccine) combined with Keytruda in high-risk melanoma patients after surgery, showing longer recurrence-free and metastasis-free survival versus Keytruda alone; safety was consistent with prior data. If confirmed, the vaccine could reshape cancer prevention and treatment and bolster mRNA vaccine credibility, but overall survival results and external validation are still pending.
A phase 3 trial of a personalised mRNA vaccine (Intismeran) given with Keytruda after melanoma surgery extended disease-free time in over 1,000 high-risk patients. While the interim results are promising, they have not yet been peer-reviewed and regulatory approval is still required before NHS rollout.
Moderna’s personalized mRNA cancer vaccine Intismeran Autogene, developed with Merck, showed Phase 3 melanoma trial success when paired with Keytruda, triggering a roughly 176% stock rally and making Moderna the S&P 500’s second-best performer this year as analysts boost bets on its cancer pipeline, though the magnitude of benefit and potential launches remain under review.
Moderna and Merck reported that their experimental mRNA cancer vaccine, intismeran, when combined with Merck’s Keytruda, produced a clinically meaningful improvement in high-risk melanoma across more than 1,100 patients, with safety consistent with prior studies; the trial could pave the way for a commercial launch next year and signals potential for an expanded mRNA cancer platform, triggering a sharp rally in Moderna’s stock and a solid gain for Merck.
Moderna and Merck report that adding the patient-specific mRNA cancer vaccine intismeran (mRNA-4157) to Merck’s Keytruda significantly extended recurrence-free and distant metastasis-free survival versus Keytruda alone in a Phase 3 trial of 1,137 melanoma patients. Interim results suggest meaningful benefit, with mature overall-survival data still pending; five-year Phase 2 data had previously shown substantial risk reductions. Full details will be presented at an upcoming conference.